Entacapone , ≥98.0% , 130929-57-6

Synonym(s):
2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide

CAS NO.：130929-57-6

Empirical Formula: C14H15N3O5

Molecular Weight: 305.29

MDL number: MFCD00866580

EINECS: 212-686-0

PRODUCT Properties

• Melting point: 162-1630C
• Boiling point: 526.6±50.0 °C(Predicted)
• Density: 1.392±0.06 g/cm3(Predicted)
• storage temp.: 2-8°C
• solubility: DMSO: soluble20mg/mL, clear
• form: powder
• pka: pKa ~4.5(at 25℃)
• color: white to light brown
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
• InChIKey: JRURYQJSLYLRLN-BJMVGYQFSA-N
• CAS DataBase Reference: 130929-57-6(CAS DataBase Reference)

Description and Uses

Entacapone was introduced in Finland, Germany and Sweden as an adjunctive treatment with L-dopa in Parkinson’s disease. Entacapone is the second drug in its class to reach the market; it can be obtained by basecatalyzed condensation of the corresponding benzaldehyde with a cyanoacetamide. Entacapone is a highly selective and orally-active catechol-0- methyltransferase (COMT) inhibitor ; by inhibiting metabolism of L-dopa when given as an adjuvant in patients with Parkinson’s disease, Entacapone markedly prolongs the effects of L-dopa and improves its bioavailability. Results from clinical studies showed that 200mglday Entacapone coadministered with L-dopa lowered the dose of the latter required to reduce fluctuations in motor performance.

This compound belongs to the cinnamic acid amides. These are amides of cinnamic acids. Used as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H315-H319
• Precautionary statements: P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313
• WGK Germany: 3
• HS Code: 2926900005
• Hazardous Substances Data: 130929-57-6(Hazardous Substances Data)